Type Joint stock company Industry Pharmaceuticals Headquarters Latvia Founded 1991 Net income 1 million EUR (2015) | Traded as Nasdaq Baltic: GRD1R Area served Worldwide Revenue 827 million EUR (2015) Number of employees 883 (2015) | |
 | ||
Key people Kirovs Lipmans (Chairman)
Juris Bundulis (CEO)
Janis Romanovskis (Chief Finance and Administrative Officer) Owner Kirovs Lipmans (33.29%))
Anna Lipmane (16.65%) Stock price GRD1R (RSE) € 4.81 -0.07 (-1.43%)10 Mar, 3:14 PM GMT+2 - Disclaimer Subsidiaries Jsc Tallinn Pharmaceutical Plant | ||
AS Grindeks (branded as Grindex), is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.
One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate. Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.
In 2015, Grindeks had a turnover revenue of €82.7 million with a profit of €1.0 million. Grindeks had 883 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anna Lipmane (16.65%)
References
Grindeks Wikipedia(Text) CC BY-SA